We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LEQVIO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
LEQVIO
Date registered
Evaluation commenced
Decision date
Approval time
236 (255 working days)
Active ingredients
inclisiran
Registration type
NCE/NBE
Indication
LEQVIO (solution for injection) is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolaemia, atherosclerotic cardiovascular disease, or at high risk of a cardiovascular event:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
- alone or in combination with other lipid-lowering therapies in patients who are statin intolerant.